BCV
BPMC

Banque Cantonale Vaudoise’s Blueprint Medicines BPMC Stock Holding History

Banque Cantonale Vaudoise’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-605
Closed -$59K – 1239
2021
Q1 		$59K Buy
+605
New +$60.4K ﹤0.01% 981

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Banque Cantonale Vaudoise's BPMC Position: Q2 2021 in Review

Banque Cantonale Vaudoise sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 605 shares — an estimated $59K sold.

Banque Cantonale Vaudoise first reported a position in BPMC in Q1 2021 and held it in 1 quarter. The position peaked at $59K in Q1 2021. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

  • Banque Cantonale Vaudoise reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 605 Blueprint Medicines shares in Q2 2021, an estimated $59K.
  • Banque Cantonale Vaudoise first reported a position in Blueprint Medicines in Q1 2021 and held it in 1 quarter.
  • Banque Cantonale Vaudoise's Blueprint Medicines position peaked at $59K in Q1 2021.
  • 281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2021, filed 11 Aug 2021.